Answers are grounded in this paper and cite their sources.
This study demonstrates improved cathodic electrochemiluminescence via a novel catalyst, suggesting potential for cancer biomarker detection.
Compared with efficient anodic luminol electrochemiluminescence (ECL), the disadvantage of cathodic ECL is that luminol cannot be electrochemically oxidized in a direct manner, and the conversion efficiency of dissolved oxygen (DO) as the coreactant to reactive oxygen species (ROS) is poor, which limits its application. Therefore, it is necessary to develop a functional catalyst suitable for the luminol-DO ECL system to directly trigger cathodic ECL. In this study, a coordination microenvironment modulation strategy was proposed. The heteroatom P was doped into the Cu single-atom catalyst (P/Cu SAs@CN), significantly enhancing the cathodic ECL emission in the luminol-DO system. The P/Cu SAs@CN catalyst facilitates a three-electron oxygen reduction reaction pathway, generating abundant ROS, particularly hydroxyl radicals, that amplify the ECL emission by oxidizing luminol anions. Simultaneously, a dual-signal amplification biosensor is developed by integrating APE1 enzyme-mediated target recycling and DNAzyme-catalyzed cleavage cycles. The biosensor achieves ultrasensitive detection of miRNA-320d, a biomarker of metastatic colorectal cancer, with the detection limit of 0.158 fM. This work not only elucidates the mechanistic link between the ORR-driven ROS generation and the ECL enhancement but also provides a versatile platform for designing advanced coreaction accelerators, which can help to address the critical demands in clinical diagnostics.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: